DOCSLIB.ORG

Hyaluronidase: Understanding Its Properties and Clinical Application for Cosmetic Injection Adverse Events

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Hyaluronidase: Understanding Its Properties and Clinical Application for Cosmetic Injection Adverse Events 1.0 ANCC CE Contact Hours Aesthetic Department Hyaluronidase: Understanding Its Properties and Clinical Application for Cosmetic Injection Adverse Events Jeanine Harrison , BScN, MN, RN-EC, NP Oriol Rhodes , RN, BAS, MBA events are seen in less than 1% of injections and they The recent global consensus on the management of cos- would be considered to be transitory in nature with neg- metic aesthetic injectable complications from hyaluronic ligible impact on the patient (Alam et al., 2015 ). Indeed, acid (HA) has increased the focus on the use of hyaluroni- the avoidance of complications through safe and effective dase more than ever before (M. Signorini et al., 2016). injection practice remains the key to preventing the need A comprehensive knowledge of facial anatomy, including to use hyaluronidase. structural positioning of facial arteries and veins, and an To understand why hyaluronidase is the recommend- extensive knowledge of HA products available for injection ed treatment for HA complications, it is important to procedures, combined with best practice protocols, will understand the nature of this compound and the potential assist to prevent adverse events. Despite the growing num- access limitations, its effect on various HAs, and the an- ber of patients using cosmetic fi llers for facial restoration, ticipated physiologic outcomes for the patient. the incidents incidence of adverse events remains low. Indeed, the avoidance of complications through safe and effective injection practice remains the key to preventing BACKGROUND the need to use hyaluronidase. Hyaluronidase is found in human and multiple sources of animals including various venoms, ovine or bovine he recent global consensus on the management testes, as well as human serum ( Ranzy, Becker-Wegerich, of cosmetic aesthetic injectable complications from Bachmann, Erdmann, & Wollina, 2009 ). T hyaluronic acid (HA) has increased the focus on The substance has been widely utilized throughout the use of hyaluronidase than ever before ( Signorini et al., medicine because of its ability to increase the degrada- 2016 ). A comprehensive knowledge of facial anatomy, in- tion extracellular matrix of HA and increase permeability cluding structural positioning of facial arteries and veins, of tissue ( Burhren et al., 2016 ). Interestingly, the physi- and an extensive knowledge of HA products available ologic theory is also seen in some gram-positive bacte- for injection procedures, combined with best practice ria, whereby the bacteria possess HA lyases, which they protocols, will assist to prevent adverse events. Despite use to assist in their penetration into the tissues (Makris, the growing number of patients using cosmetic fi llers for Wright, Ingham, & Holland, 2004 ). facial restoration, the incidents of adverse events remains low. A recent multicenter prospective cohort study, pub- PREPARATION AND DISTRIBUTION lished by Alam et al., found that complications or adverse The most common source of hyaluronidase remains to be Jeanine Harrison, BScN, MN, RN-EC, NP, is Nurse Practitioner, TH ovine and bovine, and it is produced by a recombinant DNA Medical Aesthetics, Thornhill, Ontario, Canada. methodology ( Ranzy et al., 2009 ). The recombinant DNA is Oriol Rhodes RN, BAS, MBA , is Registered Nurse, TH Medical Aesthet- purifi ed glycoproteins formed by using amino acids that are ics, Thornhill, Ontario, Canada. then placed in a sterile, nonpreserved, solution. As with any The author reports no confl icts of interest. industry, variances are common in the production of com- Address correspondence to Jeanine Harrison, BScN, MN, RN-EC, NP, pounded hyaluronidase. It may be processed differently on TH Medical Aesthetics, 8179 Yonge St, Thornhill, ON, L3T2C6, Canada (e-mail: [email protected] ). the basis of its various indications, such as cosmetic, nutra- Copyright © 2017 International Society of Plastic and Aesthetic Nurses. ceutical, pharmaceutical, or injectable grade hyaluronidase. All rights reserved. The process may also differ on the basis of the required test- DOI: 10.1097/PSN.0000000000000193 ing process for impurities. The lower the molecular weight Plastic Surgical Nursing www.psnjournalonline.com 109 Copyright © 2017 International Society of Plastic and Aesthetic Nurses. Unauthorized reproduction of this article is prohibited. Aesthetic Department of the hyaluronidase, the more signifi cant the penetration monitored. It would be considered positive, should and diffusion in the tissues. a reactive wheal form after 5 minutes of observation The recommended compound hyaluronidase salt and the wheal could last to a maximum of 30 minutes. 150 U/ml is the standard prescription in Canada for the Occasionally, this would have associated pruritus indication of HA fi ller adverse events. The average current ( Hylenex Drug Monograph, 2006 ). cost is $150.00 for a 10-ml vial (Smith’s Pharmacy Toronto, 2017). The product is to be used within 30 days and should PRACTICE IMPLICATIONS be kept refrigerated ( Hylenex Drug Monograph, 2006). Hyaluronidase preparations are generally made It is essential for clinicians to be aware that when using available in the commercial market; however, in some hyaluronidase in the clinical setting there is potential for countries, health regulations prevent the commercial varying responses, which may occur on the basis of the distribution and, thus, clinicians in Canada must uti- type of HA fi ller being targeted with the treatment. The lize compounding pharmacy preparations. Unfortu- clinician should provide a full assessment and collect all nately, when the product is a compounded substance, relevant patient health data as well as their HA injection it will not be accompanied by a drug monograph to health history. This would also include the types of HA provide the clinician with a full drug review and spe- injectable they have received and any history of reactions cifi c direction for use. It is essential that the practitioner or responses. The practitioner should attempt to acquire choose the compounding pharmacy with experience in the exact HA type, which will be treated with the hyal- compounding hyaluronidase for the use in HA adverse uronidase, and thoroughly document all information in events to ensure the appropriate preparation is created. the patient chart. Results are somewhat dependent upon the viscosity and cross-linking preparation of the HA prod- uct. In a recent study by Alam et al. (2015), an analysis of MECHANISM OF ACTION dose response and interval testing showed that the 24-mg/ Hyaluronic acid responds to hyaluronidase through a mecha- ml HA fi ller exhibited more resistance to enzymatic impact nism of breaking the glucosaminidic bond of the HA product than the 20- and 5.5-mg/ml HA products. It was conclud- and stimulating tissue absorption in the area. The destruction ed the increased HA content and cross-linking impacted of this bond changes the molecular structure, or the moiety, the ability for the hyaluronidase to degrade the product. of the product’s cohesiveness and thus allows the product A full review of the risks associated with the use of to be infi ltrated by the body’s own process for absorption of hyaluronidase and the potential for variable results should the residual by-products as a result of the dispersion ( Kassir, occur with the patient prior to the initiation of the treat- Kolluru, & Kassir, 2011). The amount of product hydroly- ment to ensure the patient has realistic understanding and sis is directly related to the quantity of hyaluronidase that is expectation of the treatment process. injected, and the full resolution of the impact of hyaluroni- An evidence-based clinical treatment protocol should be dase occurs relatively quickly and should be fully resolved developed and readily available in all clinics. The protocol by 48 hours posttreatment. It is possible that, with repeated should be followed by each injector in the clinic to ensure exposure, individuals could develop a resistance (antibodies) consistency in practice. This protocol should include not to hyaluronidase because it is a recombinant DNA source only the practical use of hyaluronidase but also the recom- ( Hylenex Drug Monograph, 2006). mended follow-up appointments, as appropriate. Hyaluronidase is the substance recommended for the treatment of adverse events with HA fi llers. Understand- CONTRAINDICATIONS ing the mechanisms of action assists the clinician in the The only true contraindication for use of hyaluronidase comprehension of treatment delivery. From the com- is in patients with known sensitivity to the medication, pounding of the product, to the biophysical results, the or any of its stabilizing components, which may be integration of knowledge improves the clinician’s skill present as a result of the compounding of the prod- and judgment, which thus will improve the outcome uct. An allergic reaction to hyaluronidase is uncommon results of this treatment in patients. and, currently, prior skin testing is considered unnec- essary because of the low incidence rate of adverse re- REFERENCES actions (0.1% urticarial or angioedema) ( Lee, Grummer, Alam , M. , Kakar , R. , Nodzenski , M. , Ibrahim , O. , Disphanurat , W. , Bolotin , D. , … Dover , J. ( 2015 ). Multicenter prospective cohort Kriegel, & Marmur, 2010 ). However, if the recipient has study of the incidence of adverse events associated with cosmetic a history of signifi cant allergies, it may be warranted to dermatologic procedures lasers, energy devices, and injectable
Load more

Recommended publications
  • Epidemiology of Mucopolysaccharidoses Update
    diagnostics Review Epidemiology of Mucopolysaccharidoses Update Betul Celik 1,2 , Saori C. Tomatsu 2 , Shunji Tomatsu 1 and Shaukat A. Khan 1,* 1 Nemours/Alfred I. duPont Hospital for Children, Wilmington, DE 19803, USA; [email protected] (B.C.); [email protected] (S.T.) 2 Department of Biological Sciences, University of Delaware, Newark, DE 19716, USA; [email protected] * Correspondence: [email protected]; Tel.: +302-298-7335; Fax: +302-651-6888 Abstract: Mucopolysaccharidoses (MPS) are a group of lysosomal storage disorders caused by a lysosomal enzyme deficiency or malfunction, which leads to the accumulation of glycosaminoglycans in tissues and organs. If not treated at an early stage, patients have various health problems, affecting their quality of life and life-span. Two therapeutic options for MPS are widely used in practice: enzyme replacement therapy and hematopoietic stem cell transplantation. However, early diagnosis of MPS is crucial, as treatment may be too late to reverse or ameliorate the disease progress. It has been noted that the prevalence of MPS and each subtype varies based on geographic regions and/or ethnic background. Each type of MPS is caused by a wide range of the mutational spectrum, mainly missense mutations. Some mutations were derived from the common founder effect. In the previous study, Khan et al. 2018 have reported the epidemiology of MPS from 22 countries and 16 regions. In this study, we aimed to update the prevalence of MPS across the world. We have collected and investigated 189 publications related to the prevalence of MPS via PubMed as of December 2020. In total, data from 33 countries and 23 regions were compiled and analyzed.
    [Show full text]
  • DRUGS REQUIRING PRIOR AUTHORIZATION in the MEDICAL BENEFIT Page 1
    Effective Date: 08/01/2021 DRUGS REQUIRING PRIOR AUTHORIZATION IN THE MEDICAL BENEFIT Page 1 Therapeutic Category Drug Class Trade Name Generic Name HCPCS Procedure Code HCPCS Procedure Code Description Anti-infectives Antiretrovirals, HIV CABENUVA cabotegravir-rilpivirine C9077 Injection, cabotegravir and rilpivirine, 2mg/3mg Antithrombotic Agents von Willebrand Factor-Directed Antibody CABLIVI caplacizumab-yhdp C9047 Injection, caplacizumab-yhdp, 1 mg Cardiology Antilipemic EVKEEZA evinacumab-dgnb C9079 Injection, evinacumab-dgnb, 5 mg Cardiology Hemostatic Agent BERINERT c1 esterase J0597 Injection, C1 esterase inhibitor (human), Berinert, 10 units Cardiology Hemostatic Agent CINRYZE c1 esterase J0598 Injection, C1 esterase inhibitor (human), Cinryze, 10 units Cardiology Hemostatic Agent FIRAZYR icatibant J1744 Injection, icatibant, 1 mg Cardiology Hemostatic Agent HAEGARDA c1 esterase J0599 Injection, C1 esterase inhibitor (human), (Haegarda), 10 units Cardiology Hemostatic Agent ICATIBANT (generic) icatibant J1744 Injection, icatibant, 1 mg Cardiology Hemostatic Agent KALBITOR ecallantide J1290 Injection, ecallantide, 1 mg Cardiology Hemostatic Agent RUCONEST c1 esterase J0596 Injection, C1 esterase inhibitor (recombinant), Ruconest, 10 units Injection, lanadelumab-flyo, 1 mg (code may be used for Medicare when drug administered under Cardiology Hemostatic Agent TAKHZYRO lanadelumab-flyo J0593 direct supervision of a physician, not for use when drug is self-administered) Cardiology Pulmonary Arterial Hypertension EPOPROSTENOL (generic)
    [Show full text]
  • 12MS6741 BQ Vol 8:Layout 1 8/13/12 2:10 PM Page 1
    12MS6741_BQ_Vol_8:Layout 1 8/13/12 2:10 PM Page 1 BioTherapeutics B Quarterly Volume 8/Summer 2012 Diagnostic and Pharmaceutical News for You and Your Medical Practice $4.95 Diagnostics I Pharmaceuticals I DxRx Solutions I Continuing Education I News 12MS6741_BQ_Vol_8:Layout 1 8/13/12 2:10 PM Page 2 Choose the Only FDA-approved Hyaluronidase Synthesized by a Recombinant Process OTHER clinically utilized hyaluronidase productscts contain cattle or sheep testes-derived hyaluronidase Hylenex® recombinant (hyaluronidase human injection) is a Safe, Effective and Low Cost Option* • Hylenex recombinant is: – the ONLY recombinant human hyaluronidase available and – the lowest priced FDA-approved hyaluronidase available.* Hylenex® Vitrase® Wydase® Hydase Amphadase® Compounded recombinant Not Since Not Since Not Since Available for Use YES YES 1999 2008 2010 YES FDA-approved YES YES YES YES YES NO FDA-regulated Manufacturing YES YES Not Currently Not Currently Not Currently NO (cGMP**) Made Made Made Recombinant Sheep Cattle Cattle Cattle Cattle Source of Active Ingredient Human Testes Testes Testes Testes Testes Units/mL 150 200 150 150 150 150 *Cost comparison based on published Wholesale Acquisition Cost per single-use vial comparing FDA-approved available products. Red Book March 2012. Price comparison is not indicative of fi nal customer price and is not intended to be a comparison of safety or effi cacy of drugs. **cGMP= Current Good Manufacturing Practices See Important Safety Information and Brief Summary of Full Prescribing Information. BioTherapeutics
    [Show full text]
  • Label, Multicenter, Single Arm Study in Fifty-One (51) Patients
    NDA 21-859/S-009 Page 3 HIGHLIGHTS OF PRESCRIBING INFORMATION • Hypersensitivity (4) _______________ _______________ These highlights do not include all the information needed to use WARNINGS AND PRECAUTIONS HYLENEX recombinant safely and effectively. See full prescribing • Spread of Localized Infection. (5.1) information for HYLENEX recombinant. • Ocular Damage. (5.2) • Enzyme Inactivation with Intravenous Administration. (5.3) ____________________ ____________________ HYLENEX recombinant (hyaluronidase human injection) ADVERSE REACTIONS Initial U.S. Approval: 2005 • Allergic and anaphylactic-like reactions have been reported, rarely (6) __________________ _________________ INDICATIONS AND USAGE To report SUSPECTED ADVERSE REACTIONS, contact Halozyme HYLENEX recombinant is a tissue permeability modifier indicated as an Therapeutics, Inc. at 1-877-877-1679 or FDA at 1-800-FDA-1088 or adjuvant www.fda.gov/medwatch. • ____________________ ____________________ in subcutaneous fluid administration for achieving hydration (1.1) DRUG INTERACTIONS • to increase the dispersion and absorption of other injected drugs (1.2) • Furosemide, the benzodiazepines and phenytoin are incompatible with • in subcutaneous urography for improving resorption of radiopaque hyaluronidase (7.1) agents (1.3) • _______________ ______________ Hyaluronidase should not be used to enhance the absorption and DOSAGE AND ADMINISTRATION dispersion of dopamine and/or alpha agonist drugs (7.2) • Subcutaneous fluid administration: • Local anesthetics: Hyaluronidase hastens onset
    [Show full text]
  • Enzymes for Cell Dissociation and Lysis
    Issue 2, 2006 FOR LIFE SCIENCE RESEARCH DETACHMENT OF CULTURED CELLS LYSIS AND PROTOPLAST PREPARATION OF: Yeast Bacteria Plant Cells PERMEABILIZATION OF MAMMALIAN CELLS MITOCHONDRIA ISOLATION Schematic representation of plant and bacterial cell wall structure. Foreground: Plant cell wall structure Background: Bacterial cell wall structure Enzymes for Cell Dissociation and Lysis sigma-aldrich.com The Sigma Aldrich Web site offers several new tools to help fuel your metabolomics and nutrition research FOR LIFE SCIENCE RESEARCH Issue 2, 2006 Sigma-Aldrich Corporation 3050 Spruce Avenue St. Louis, MO 63103 Table of Contents The new Metabolomics Resource Center at: Enzymes for Cell Dissociation and Lysis sigma-aldrich.com/metpath Sigma-Aldrich is proud of our continuing alliance with the Enzymes for Cell Detachment International Union of Biochemistry and Molecular Biology. Together and Tissue Dissociation Collagenase ..........................................................1 we produce, animate and publish the Nicholson Metabolic Pathway Hyaluronidase ...................................................... 7 Charts, created and continually updated by Dr. Donald Nicholson. DNase ................................................................. 8 These classic resources can be downloaded from the Sigma-Aldrich Elastase ............................................................... 9 Web site as PDF or GIF files at no charge. This site also features our Papain ................................................................10 Protease Type XIV
    [Show full text]
  • Separation of Oligosaccharides from Lotus Seeds Via Medium-Pressure Liquid Chromatography Coupled with ELSD and DAD
    www.nature.com/scientificreports OPEN Separation of Oligosaccharides from Lotus Seeds via Medium- pressure Liquid Chromatography Received: 20 September 2016 Accepted: 06 February 2017 Coupled with ELSD and DAD Published: 09 March 2017 Xu Lu1,2,3, Zhichang Zheng1, Song Miao2, Huang Li1, Zebin Guo1,3, Yi Zhang1,3, Yafeng Zheng1,3, Baodong Zheng1,3 & Jianbo Xiao1,4 Lotus seeds were identified by the Ministry of Public Health of China as both food and medicine. One general function of lotus seeds is to improve intestinal health. However, to date, studies evaluating the relationship between bioactive compounds in lotus seeds and the physiological activity of the intestine are limited. In the present study, by using medium pressure liquid chromatography coupled with evaporative light-scattering detector and diode-array detector, five oligosaccharides were isolated and their structures were further characterized by electrospray ionization-mass spectrometry and gas chromatography-mass spectrometry. In vitro testing determined that LOS3-1 and LOS4 elicited relatively good proliferative effects onLactobacillus delbrueckii subsp. bulgaricus. These results indicated a structure-function relationship between the physiological activity of oligosaccharides in lotus seeds and the number of probiotics applied, thus providing room for improvement of this particular feature. Intestinal probiotics may potentially become a new effective drug target for the regulation of immunity. Lotus seeds are mature seeds of Nelumbo nucifera Gaertn and are so far the oldest plant seeds currently known. In China, lotus seeds have been traditionally used as both pharmaceutical and food resource. Bioactive ingredi- ents such as water-soluble carbohydrates, alkaloids, flavonoids, and superoxide dismutase (SOD) render various bioactivities to lotus seeds that regulate intestinal and stomach functions, prevent oxidation, lower blood glucose, and boost immunity.
    [Show full text]
  • Mutagenesis of Human Alpha-Galactosidase a for the Treatment of Fabry Disease
    City University of New York (CUNY) CUNY Academic Works All Dissertations, Theses, and Capstone Projects Dissertations, Theses, and Capstone Projects 9-2017 Mutagenesis of Human Alpha-Galactosidase A for the Treatment of Fabry Disease Erin Stokes The Graduate Center, City University of New York How does access to this work benefit ou?y Let us know! More information about this work at: https://academicworks.cuny.edu/gc_etds/2338 Discover additional works at: https://academicworks.cuny.edu This work is made publicly available by the City University of New York (CUNY). Contact: [email protected] CITY COLLEGE, CITY UNIVERSITY OF NEW YORK MUTAGENESIS OF HUMAN ALPHA-GALACTOSIDASE A FOR THE TREATMENT OF FABRY DISEASE By Erin Stokes A dissertation submitted to the Graduate Faculty in Biochemistry in partial fulfillment of the requirement for the degree of Doctor of Philosophy, The City University of New York 2017 ©2017 Erin Stokes All rights reserved ii Mutagenesis of Human α-Galactosidase A for the Treatment of Fabry Disease By Erin Stokes This manuscript has been read and accepted for the Graduate Faculty Biochemistry in satisfaction of the dissertation requirement for the degree of Doctor of Philosophy. ______________________ David H. Calhoun Date Chair of Examining Committee ______________________ Richard Magliozzo Date Executive Officer Supervisory Committee: Haiping Cheng (Lehman College, CUNY) M. Lane Gilchrist (City College of New York, CUNY) Emanuel Goldman (New Jersey Medical School, Rutgers) Kevin Ryan (City College of New York, CUNY) THE CITY UNIVERSITY OF NEW YORK iii Abstract Mutagenesis of Human α-Galactosidase A for the Treatment of Fabry Disease By Erin Stokes Advisor: Dr.
    [Show full text]
  • Modelling Reactions Catalysed by Carbohydrate-Active Enzymes
    bioRxiv preprint doi: https://doi.org/10.1101/008615; this version posted November 12, 2014. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license. Modeling Reactions Catalyzed by Carbohydrate-Active Enzymes Önder Kartal, Oliver Ebenhöh November 12, 2014 Abstract Carbohydrate polymers are ubiquitous in biological systems and their roles are highly diverse, ranging from energy storage over mechanical sta- bilisation to mediating cell-cell or cell-protein interactions. The functional diversity is mirrored by a chemical diversity that results from the high flexi- bility of how different sugar monomers can be arranged into linear, branched or cyclic polymeric structures. Mathematical models describing biochemi- cal processes on polymers are faced with various difficulties. First, polymer- active enzymes are often specific to some local configuration within the poly- mer but are indifferent to other features. That is they are potentially active on a large variety of different chemical compounds, meaning that polymers of different size and structure simultaneously compete for enzymes. Second, especially large polymers interact with each other and form water-insoluble phases that restrict or exclude the formation of enzyme-substrate complexes. This heterogeneity of the reaction system has to be taken into account by explicitly considering processes at the, often complex, surface of the poly- mer matrix. We review recent approaches to theoretically describe polymer biochemical systems. All attempts address a particular challenge, which we discuss in more detail.
    [Show full text]
  • Hyaluronidases: Their Genomics, Structures, and Mechanisms of Action
    Chem. Rev. 2006, 106, 818−839 818 Hyaluronidases: Their Genomics, Structures, and Mechanisms of Action Robert Stern† and Mark J. Jedrzejas*,‡ Children’s Hospital Oakland Research Institute, Oakland, California 94609, and Department of Pathology and UCSF Comprehensive Cancer Center, School of Medicine, University of California, San Francisco, California 94143-0511 Received April 26, 2005 Contents 8. Bacterial Hyaluronidases: Their Structure and 833 Mechanism of Action 1. Introduction 818 8.1. Polymeric Glycan-Binding Cleft: A Common 833 1.1. Overview of the Hyaluronidases 818 Feature of the Hyaluronidases and Other 1.2. Assays for Hyaluronidase Activity 820 Glycan-Degrading Enzymes 1.3. Eukaryote Hydrolase-Type of Hyaluronidases 820 8.2. Domain Structure Bacterial Hyaluronidases 834 1.4. Prokaryote Eliminase-Type of Hyaluronidases 820 8.3. Mechanism of Hyaluronan Degradation by 834 1.5. endo-â-Glucuronidase-Type of 820 Bacterial Hyaluronan Lyases Hyaluronidases 8.4. Streptomyces hyalurolyticus Hyaluronan 836 1.6. Fungal Hyaluronidases 820 Lyase 2. Hyaluronan as a Substrate for Catalysis 820 9. Summary 836 3. Properties of the Hyaluronidases 821 9.1. Conclusions 836 3.1. Designation of Hyaluronidases as a Class 821 9.2. Future Directions 836 within the Glycosidase Families of Enzymes 10. Abbreviations 837 3.2. The Term "Hyaluronidase" Is a Misnomer 822 11. Acknowledgments 837 3.3. Evolution of Hyaluronidases Can Be 822 12. Supporting Information 837 Postulated from Their Substrate Specificity 13. References 837 3.4. Digestion Products of Human and Bacterial 823 Hyaluronidase Catalysis 4. Identification of Mechanism of Hyaluronan 823 1. Introduction Degradation by Vertebrate-like Hyaluronidases 4.1. Catalytic Mechanism and Its Importance 823 1.1.
    [Show full text]
  • Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act
    Updated June 07, 2021 Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act Three categories of bulk drug substances: • Category 1: Bulk Drug Substances Under Evaluation • Category 2: Bulk Drug Substances that Raise Significant Safety Risks • Category 3: Bulk Drug Substances Nominated Without Adequate Support Updates to Categories of Substances Nominated for the 503B Bulk Drug Substances List1 • Add the following entry to category 2 due to serious safety concerns of mutagenicity, cytotoxicity, and possible carcinogenicity when quinacrine hydrochloride is used for intrauterine administration for non- surgical female sterilization: 2,3 o Quinacrine Hydrochloride for intrauterine administration • Revision to category 1 for clarity: o Modify the entry for “Quinacrine Hydrochloride” to “Quinacrine Hydrochloride (except for intrauterine administration).” • Revision to category 1 to correct a substance name error: o Correct the error in the substance name “DHEA (dehydroepiandosterone)” to “DHEA (dehydroepiandrosterone).” 1 For the purposes of the substance names in the categories, hydrated forms of the substance are included in the scope of the substance name. 2 Quinacrine HCl was previously reviewed in 2016 as part of FDA’s consideration of this bulk drug substance for inclusion on the 503A Bulks List. As part of this review, the Division of Bone, Reproductive and Urologic Products (DBRUP), now the Division of Urology, Obstetrics and Gynecology (DUOG), evaluated the nomination of quinacrine for intrauterine administration for non-surgical female sterilization and recommended that quinacrine should not be included on the 503A Bulks List for this use. This recommendation was based on the lack of information on efficacy comparable to other available methods of female sterilization and serious safety concerns of mutagenicity, cytotoxicity and possible carcinogenicity in use of quinacrine for this indication and route of administration.
    [Show full text]
  • Cazymes Catalogue 2021
    cazymes 2021 Visit the Online Store www.nzytech.com Newsletter NZYWallet Instantaneous Quotes Subscribe our newsletter to receive NZYWallet is a prepaid account Do you need an urgent quote? Just awesome news and promotions. that oers the flexibility you need add your products to Cart, proceed to focus on your research. With to Checkout, select quote and it’s NZYWallet you can buy any done! product from our Online Store, check your up-to-date balance and track your latest orders. Contact our customer service at [email protected] or your local sales representative for more information. Follow us: 2021 NZYTech NZYTech 2 Visit the Online Store www.nzytech.com Newsletter NZYWallet Instantaneous Quotes Subscribe our newsletter to receive NZYWallet is a prepaid account Do you need an urgent quote? Just awesome news and promotions. that oers the flexibility you need add your products to Cart, proceed to focus on your research. With to Checkout, select quote and it’s NZYWallet you can buy any done! product from our Online Store, check your up-to-date balance and track your latest orders. Contact our customer service at [email protected] or your local sales representative for more information. Follow us: cazymes 3 4 2021 NZYTech NZYTech OVERVIEW 8 GLYCOSIDE HYDROLASES 10 Acetylgalactosaminidases Acetylglucosaminidases Agarases Amylases @ a glance Amylomaltases Arabinanases Arabinofuranosidases Arabinopyranosidases Arabinoxylanases Carrageenases Cellobiohydrolases Cellodextrinases Cellulases Chitinases Chitosanases Dextranases Fructanases Fructofuranosidases
    [Show full text]
  • Protein List
    Protein Accession Protein Id Protein Name P11171 41 Protein 4.
    [Show full text]